Work

Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy

Year: 2021

Type: article

Abstract: Long-Term Follow-up of CAR T-Cell–Treated Lymphoma Progression-free survival at 5 years was 31% in patients with diffuse large B-cell lymphoma and 43% in patients with follicular lymphoma. A total ...

Source: New England Journal of Medicine

DOI: 10.1056/nejmc2030164

Authors: Elise A. Chong, Marco Ruella, Stephen J. Schuster

Institution: University of Pennsylvania

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Research Foundation, Chung-Ang University, National Research Foundation of Korea, National Cancer Institute

Awards: Resistance To Targeted Immunotherapies:CART19 as a Paradigm, Resistance To Targeted Immunotherapies:CART19 as a Paradigm, G6079785670, G6598968374

OpenAlex ID: W3132778321

FWCI: 21.64

Cites: 5

Cited by: 341

Related to: 10